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Since nephrotoxicity is dose limiting for cisplatin, several
attempts have been made to improve the therapeutic index of
cisplatin. One way to achieve this goal was to reduce toxicity
by giving cisplatin in a slow i.v. infusion instead of i.v. bolus
injection (Lokich, 1980; Loo et al., 1978). Pharmacokinetic
studies showed no change in the AUC (area under the con-
centration x time curve) of free cisplatin whether the same
dose of cisplatin (100mgm-2) was administered by rapid
infusion or by short- or long-term infusion (Patton et al.,
1982; Vermorken et al., 1989) and Campbell et al. (1983)
reported a correlation between total platinum plasma levels
and the devlopment of nephrotoxicity. Although the
mechanism of nephrotoxicity induced by cisplatin remains
undefined, these data suggest that nephrotoxicity depends on
peak plasma concentration more than on AUC. In a
previous study we confirmed this suggestion (Los et al.,
1989a), demonstrating that renal toxicity was more severe at
higher Pt peak levels than at lower levels with comparable
AUC's. In analogy with the i.v. administration, in which
cisplatin is given in prolonged infusions to reduce toxicity, a
slow release system for cisplatin has been developed in our
institute (Deurloo et al., 1990). We have used this polymer
hydrogel system in an attempt to improve i.p. chemotherapy
by implantation into the peritoneal cavity. This system
releases cisplatin over several hours and is co-administered
with a large volume of NaCl comparable with that normally
used in i.p. cisplatin treatment. We report here out studies
using this slow release system for i.p. chemotherapy to
investigate antitumour response for cancers restricted to
peritoneal cavity in relation to the induced nephrotoxicity.
Male WAG/Rij rats, 8-12 weeks old at the time of the
experiments, were obtained from the animal department of
The Netherlands Cancer Institute. To obtain peritoneal
tumours, 2 x 106CC531 tumour cells were inoculated i.p.
Four weeks later, small peritoneal tumour nodules were pres-
ent in 80 to 100% of the rats (Los et al., 1989b).
Cis-diamminedichloroplatinum(II) (PlatinolR) (Bristol
Myers) was used for i.p. administration. Cisplatin (Ventron,
Karlsruhe, Germany), obtained as a crystalline powder, was
used for incorporation to the slow release device, obtained
from the TNO Centre for Polymeric Materials, Delft, The
Netherlands. The hydrogel MD24 rods used in this study are
the same as the T3 rods described in a previous study
(Deurloo et al., 1990).
Platinum in tumours, plasma and peritoneal fluid were
detected after i.p. chemotherapy with cDDP and MD24 by
Flameless Atomic Absorption Spectroscopy. Samples
preparation is described in detail elsewhere (Los et al.,
1989a). Cisplatin was injected i.p. in a volume of 20 ml 0.9%
NaCL solution. MD24 was inserted into the peritoneal cavity
with a trocar (inner diameter 1.75 mm) under ether anaes-
thesia followed by an i.p. injection of a 0.9% NaCl solution
(20 ml). The length of administered rods was adjusted to
obtain a dose of 5 mg cDDP kg-' rat (MD24/5), and varied
between 5-8 mm. Tumour tissue was collected at 24, 48 and
168 h after treatment. Pharmacokinetic studies were per-
formed both for free cDDP as for cDDP built into MD24
rods in a similar way as described earlier (Los et al., 1989a).
Pharmacokinetics of MD24 and cDDP were determined in
plasma and peritoneal fluid. The cumulative release of cDDP
from MD24 rods was 53% in 4 h and 82% in I day. The
same batch of rods were used in the rat studies. No
significant differences in AUC's were detected in the
peritoneal fluid after treatment with MD24/5 and free cDDP
(5 mg kg-') (Table I). In plasma, a higher AUC was
recorded only for total Pt after MD24/5 treatment compared
with that after free cDDP (Table I). The time to reach
maximum concentrations (Tmax) for total Pt in plasma was
440 min longer for MD24/5 than for free cDDP (480 min vs
40 min). The equivalent delay for the ultrafiltrate was 80 min
(120 min vs 40 min). These differences were due to the slow
release properties of MD24/5. The maximal peak concentra-
tion (Cm.) for total and ultrafiltered Pt was strongly reduced
in plasma after treatment with MD24/5 in comparison with
cDDP. This was also the case in the peritoneal cavity (Table
I). These results indicate some pharmacokinetic advantages
for MD24/5 compared with cDDP, such as a lower Cmax in
plasma despite a comparable AUC for free platinum in
plasma, which might reduce the dose limiting renal toxicity.
Platinum concentrations in whole tumours were measured
at different times (24, 48 and 168 h) after administration of
MD24/5, cDDP (5 mg kg-') or a combination of both (50%
of the MD24/5 dose + 50% of the CDDP dose). After
similar drug doses, tumour Pt concentrations were com-
parable after 7 days (Figure 1). Higher tumour Pt concentra-
tions were detected after treatment with MD24/5 at days 1
and 2. This might be due to a prolonged exposure of the
tumour to cDDP in the peritoneal cavity or to higher Pt
plasma concentrations which might affect the ultimate
tumour Pt concentration. An important finding was that the
lower peak platinum concentrations in plasma and peritoneal
cavity did not affect the drug uptake into peritoneal tumours.
It seemed that the uptake of cDDP into peritoneal tumours
depended on tumour exposure (AUC) and not on cDDP
peak levels (Cmax) in peritoneal cavity and plasma. This is an
agreement with a previous study, in which the uptake of
cDDP from plasma was AUC dependent (Los et al., 1989a).
Creatinine peak levels were measured in plasma on days 5
to 7, to determine the extent of renal toxicity. Creatinine
levels in plasma decreased when the same dose of cDDP was
incorporated into the slow release system MD24 (Figure 2).
From the data presented in Figure 2, a dose of 7.75 mg kg-'
cDDP incorporated into MD24 rods was calculated to give
similar plasma creatinine levels as were demonstrated after an
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Table I Pharmacokinetic data in plasma and peritoneal cavity after i.p. treatment
with cDDP (5 mg kg') and cDDP (5 mg kg-') containing rods (MD24)
MD24 cDDP
Parameter Total Pt Free Pt Total Pt Free Pt
AUCpiasma (0-24h) 181.5± 1.4 21.5± 1.1 98± 14 22.3±7.2
Tmax (plasma) 480 10 120 + 35 40 ± 8.6 40 ± 10
Cmax (plasma) 9.3 0.8 2.9 0.3 17 2.6 11 1.7
AUCPC (0-24 h) 590 136 368.7 96 481.7 110 338.8 38
Tmax (p.c.) 240 10 240 70 0 0
Cmax (p.C.) 110 4 52 1 250 27 240 31
p.c. = peritoneal cavity, AUC = Area under the concentration x time curve (jiM min),
Tmax (min), Cmax (I"M).
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Figure I Platinum concentrations in peritoneal tumours after
treatment with 5 mg kg-' cDDP (_), MD24/5 rods (L=) or
2.5 mg kg- free cDDP combined with MD24/2.5 ( ).
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Figure 2 Creatinine peak levels in plasma after treatment with
cDDP (3, 5, 6, 7mg kg-') (U) and MD24 rods (containing 5, 7
and 9 mg kg-' cDDP) (0). Mean ± s.d.
i.p. cDDP bolus injection of 5 mg kg-'. These data indicated
that cDDP formulated in a slow release system reduced renal
toxicity. An explanation might be the lower Cn,, for cDDP
in plasma after treatment with MD24. Current evidence in
humans suggests that single courses of cDDP in the range of
50 mg m2 body surface area will produce reversible renal
toxicity in one quarter to one third of the patients treated
(Highly et al., 1973; Madias & Harrington, 1978). A similar
incidence of reversible toxicity was demonstrated with the
Figure 3 Survival of tumour bearing rats ( ) and after treat-
ment with 3mg kg-' cDDP (- ), Smgkg-' cDDP (----)
and after treatment with MD24/5 (---). For statistical analysis
the Wilcoxon (Breslow) test was used.
regimen of 20 mg m-2 body surface area administered for five
days (Daugaard et al., 1987; Daugaard & Abildgaard, 1989).
This means that more cDDP can be administered without
increasing renal toxicity if Pt peak concentrations in plasma
are reduced. The same phenomenon is described in this paper
when cDDP was built into rods leading to a prolonged
release and lower Pt peak concentrations.
The antitumour response was measured by survival of
tumour bearing rats. Two different treatment schemes were
compared, i.e. equitoxic doses of free cDDP (3 mg kg-') and
cDDP (5 mg kg-') incorporated into MD24 rods, and
equimolar doses of free cDDP (5 mg kg-') and cDDP
(5 mg kg-') incorporated into MD24 rods. Ten rats were
treated with equitoxic doses 3 mg kg-' cDDP or 5 mg kg-'
cDDP incorporated into MD24 rods. The peak creatinine
levels after 3 mg kg-' cDDP and MD24/5 rods were
121 ± 10 liM and 110 ± 22 jiM respectively. A third group of
ten rats was treated with 5 mg kg-' cDDP, in which
creatinine levels in plasma were 320 ± 23 gM, i.e. almost a
3-fold increase in comparison with the same cDDP dose
incorporated into MD24 rods. All treatments increased sur-
vival time compared with the conrol group (P <0.001)
(Figure 3). Further these data demonstrated no significant
differences in survival after MD24/5 treatment compared
with an equimolar cDDP (5 mg kg-') treatment. The similar
platinum concentration in peritoneal tumours after equimolar
treatment (Figure 1) were in line with these survival data. It
would be expected, however from a pharmacological point of
view, that increasing the cDDP dose from 3 mg kg-',
administered as a free cDDP, to 5 mg kg-' incorporated in a
slow release system would lead to an enhanced tumour
exposure and be consequently followed by a better tumour
response. A possible explanation why this did not occur
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might be the fact that the volume of the installed fluid was
cleared too rapidly from the peritoneal cavity. At the time of
installation of the MD24 rods, 20 ml offluid is present, while
15 ml of the 20 ml will be cleared within 6h. (Los et al.,
1989a). Six hours after installation, when 55% of the drug
had been released from the rod, the volume of the remaining
fluid (5 ml) may be too small to guarantee a homogeneous
distribution of cDDP in the peritoneal cavity (Rosenshein et
al., 1978; Dunnick et al., 1979). This would mean that not all
tumours in the peritoneal cavity were exposed to the same
quantity of drug, leading to a smaller tumour response than
expected based on the higher dose.
In conclusion, renal toxicity, due to cDDP treatment,
could be reduced by using a slow drug release system
implanted intraperitoneally. The antitumour response, how-
ever, did not increase after treatment at an equitoxic level,
leaving the therapeutic ratio unchanged. Inhomogeneous
peritoneal drug distribution may have compromised the
result with the slow release treatment.
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